Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Oncology Reports|May 19, 2011
Growth-suppressive activities of serine protease inhibitors, FOY-305, ONO-3403 and FO-349 toward human carcinoma cellsM Ohkoshi, T Denda, T Hiwasa
Gan to Kagaku Ryoho. Cancer & Chemotherapy|April 1, 1990
[Quality of life in gastrointestinal cancer chemotherapy--from the standpoint of cancer chemotherapy]M Kurihara, T Izumi, T Denda, et al.
Journal of Gastroenterology and Hepatology|July 1, 1995
Chemosensitivity test for repeated arterial infusion chemotherapy by reservoir for unresectable hepatocellular carcinomaT Denda, H Saisho, M Yoshikawa, et al.
Plant Molecular Biology|September 1, 1995
Intron length variation of the Adh gene in Brachyscome (Asteraceae)T Denda, K Kosuge, K Watanabe, et al.
Nihon Rinsho. Japanese Journal of Clinical Medicine|July 1, 1993
[Treatment of common bile duct stones by peroral cholangioscopy]T Tsuyuguchi, H Saisho, T Yamaguchi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 11, 2011
Cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer: results from the randomised phase II part of a phase I/II studyT Kato, K Muro, K Yamaguchi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 26, 2013
Impact of excision repair cross-complementing gene 1 (ERCC1) on the outcomes of patients with advanced gastric cancer: correlative study in Japan Clinical Oncology Group Trial JCOG9912Y Yamada, N Boku, T Nishina, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 4, 2018
REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patientsK Shitara, T Yamanaka, T Denda, et al.
ESMO Open|December 12, 2022
A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in patients with metastatic colorectal cancer (WJOG7612GTR)W Okamoto, K Sakai, A Makiyama, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 25, 2015
FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE studyS Iwamoto, T Takahashi, H Tamagawa, et al.
Pageof 2